Related Experiment Videos
Alpha1-adrenergic receptor subtypes in human detrusor
B J Malloy1, D T Price, R R Price
1Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA.
The Journal of Urology
|August 28, 1998
Summary
Human detrusor muscle expresses alpha-1 adrenergic receptors (alpha1ARs), primarily the alpha1d subtype, unlike rat models. This finding suggests alpha1dARs may be key targets for treating bladder dysfunction.
Area of Science:
- Pharmacology
- Urology
- Molecular Biology
Background:
- Alpha-1 adrenergic receptors (alpha1ARs) play a crucial role in bladder smooth muscle contraction.
- Understanding the specific subtypes of alpha1ARs expressed in the human detrusor is essential for targeted pharmacological interventions.
Purpose of the Study:
- To identify and quantify the expression of alpha1-adrenergic receptor (alpha1AR) subtypes within the human detrusor muscle.
- To compare the alpha1AR subtype expression profile in human detrusor with that of rat bladder tissue.
Main Methods:
- Saturation binding assays using [125I]HEAT to detect alpha1ARs in human detrusor.
- RNase protection assays and RT-PCR to determine mRNA expression levels of alpha1a, alpha1b, and alpha1d subtypes in human and rat bladder tissues.
- Competition binding analysis with BMY7378 to quantify alpha1dAR protein expression in human detrusor.
Main Results:
- Alpha1AR expression in human detrusor was found to be low but reproducible.
- Human detrusor predominantly expressed alpha1dAR mRNA (66%) and protein (66%), with lower levels of alpha1aAR (34%) and no detectable alpha1bAR.
- Rat bladder exhibited a different mRNA expression profile, with roughly equal proportions of alpha1a, alpha1b, and alpha1d subtypes.
Conclusions:
- The human detrusor expresses alpha1dAR and alpha1aAR subtypes, with a significant predominance of alpha1dAR.
- This subtype distribution in human detrusor differs markedly from that observed in rat bladder.
- The findings suggest that alpha1dARs in the human bladder may represent a novel therapeutic target for managing irritative bladder symptoms.